HER2-targeted therapies have revolutionized the treatment landscape of patients with HER2-positive (immunohistochemical (IHC) 3+/or IHC2+ and in situ hybridization (ISH) positive score) BC [5]; therefore, testing for HER2 overexpression is considered standard practice during the diagnosis and workup of new patients [6]. The gene discussed is ERBB2; the disease is breast cancer.